The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to offer a greater substantial reduction in body mass and benefit metabolic function, particularly co